Savant Capital LLC Acquires 31,421 Shares of Kenvue Inc. $KVUE

Savant Capital LLC increased its holdings in shares of Kenvue Inc. (NYSE:KVUE) by 186.0% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 48,311 shares of the company’s stock after buying an additional 31,421 shares during the period. Savant Capital LLC’s holdings in Kenvue were worth $833,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also modified their holdings of KVUE. Cornerstone Planning Group LLC raised its stake in shares of Kenvue by 705.2% during the third quarter. Cornerstone Planning Group LLC now owns 1,554 shares of the company’s stock worth $25,000 after buying an additional 1,361 shares during the last quarter. Physician Wealth Advisors Inc. raised its stake in shares of Kenvue by 67.5% during the fourth quarter. Physician Wealth Advisors Inc. now owns 1,533 shares of the company’s stock worth $26,000 after buying an additional 618 shares during the last quarter. Elyxium Wealth LLC bought a new stake in shares of Kenvue during the fourth quarter worth approximately $26,000. SBI Securities Co. Ltd. raised its stake in shares of Kenvue by 82.4% during the fourth quarter. SBI Securities Co. Ltd. now owns 2,273 shares of the company’s stock worth $39,000 after buying an additional 1,027 shares during the last quarter. Finally, Atlantic Union Bankshares Corp increased its stake in Kenvue by 184.1% in the third quarter. Atlantic Union Bankshares Corp now owns 2,619 shares of the company’s stock valued at $43,000 after purchasing an additional 1,697 shares in the last quarter. 97.64% of the stock is owned by institutional investors.

Kenvue Stock Down 0.2%

Shares of KVUE stock opened at $17.32 on Wednesday. The firm has a fifty day moving average of $17.40 and a 200-day moving average of $17.47. The company has a quick ratio of 0.70, a current ratio of 0.98 and a debt-to-equity ratio of 0.67. Kenvue Inc. has a 12-month low of $14.02 and a 12-month high of $23.63. The company has a market capitalization of $33.25 billion, a price-to-earnings ratio of 20.38, a P/E/G ratio of 1.32 and a beta of 0.54.

Kenvue (NYSE:KVUE) last issued its quarterly earnings data on Thursday, May 7th. The company reported $0.32 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.27 by $0.05. Kenvue had a net margin of 10.61% and a return on equity of 20.81%. The company had revenue of $3.91 billion during the quarter, compared to the consensus estimate of $3.84 billion. During the same quarter in the prior year, the firm earned $0.24 earnings per share. The firm’s revenue was up 4.5% compared to the same quarter last year. As a group, equities research analysts predict that Kenvue Inc. will post 1.16 earnings per share for the current fiscal year.

Kenvue Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Wednesday, May 27th. Stockholders of record on Wednesday, May 13th were given a dividend of $0.2075 per share. The ex-dividend date of this dividend was Wednesday, May 13th. This represents a $0.83 annualized dividend and a dividend yield of 4.8%. Kenvue’s dividend payout ratio is currently 97.65%.

Insider Activity

In other news, General Counsel Matthew Orlando sold 38,491 shares of the stock in a transaction on Friday, May 8th. The shares were sold at an average price of $17.66, for a total transaction of $679,751.06. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. 1.59% of the stock is owned by corporate insiders.

Analysts Set New Price Targets

Several brokerages have commented on KVUE. Zacks Research raised shares of Kenvue from a “hold” rating to a “strong-buy” rating in a research note on Friday, May 8th. Argus raised shares of Kenvue to a “hold” rating in a research note on Friday, March 6th. Barclays lowered their target price on shares of Kenvue from $19.00 to $18.00 and set an “equal weight” rating for the company in a research note on Tuesday, April 14th. Weiss Ratings downgraded shares of Kenvue from a “hold (c)” rating to a “hold (c-)” rating in a research note on Friday. Finally, Canaccord Genuity Group upped their target price on shares of Kenvue from $17.00 to $18.00 and gave the company a “hold” rating in a research note on Wednesday, February 18th. One investment analyst has rated the stock with a Strong Buy rating, three have given a Buy rating and twelve have given a Hold rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Hold” and a consensus price target of $19.33.

Kenvue Company Profile

Kenvue is a consumer health company that was established as a standalone, publicly traded business after separating from Johnson & Johnson. Listed on the New York Stock Exchange under the symbol KVUE, Kenvue focuses on the development, manufacture, marketing and distribution of consumer health and personal care products across a range of categories including skin and beauty care, baby care, oral care, wound care and over‑the‑counter medicines.

The company owns and markets a portfolio of widely recognized consumer brands, including names familiar to global shoppers across retail and pharmacy channels.